행사/교육
Pharma Pricing & Market Access Outlook Europe 2013
- 등록일2013-02-25
- 조회수4161
- 구분 국외
- 행사교육분류 행사
-
주관기관
Health Network Communications Ltd
-
행사장소
The Royal Horseguards Hotel - London
-
행사기간
2013-03-19 ~ 2013-03-22
- 원문링크
- 첨부파일
brochure.pdf
Pharma Pricing & Market Access Outlook Europe 2013
Conference programme
Pre-conference workshop: Tuesday 19th March 2013
Workshop One
Understanding Payers and their Recent Actions
09.00 Introductions
09.10 Global Market Access and Pricing (MA&P) overview
09.40 Global Payer Segments, their characteristics and requirements
10.30 Morning break
10.45 Global health care funding challenges - What issues are payers facing and how are they handling them?
11.45 Payer Benefits Analysis: Structured analysis of payer needs
12.30 Lunch
13.30 Case studies: Specific drug situations, issues encountered and potential solutions. Three specific drug cases will be analyzed from a payer and industry perspective
15.00 Afternoon break
15.15 An overview and discussion of recent and ongoing country MA&P system changes and their implications
16.15 Can drug companies and payers collaborate?
Day One, Wednesday 20th March 2013
Conference
08.00 Registration
09.00 Chair’s opening presentation: Overview of current issues and trends in global market access and pricing
› Mr Ed Schoonveld, Principal, ZS Associates Inc
Chair’s opening presentation: Overview of current issues and trends in global market access and pricing
09.30 Keynote panel discussion: Pharmaceutical pricing & access in the age of austerity
› Mr Andras Fehervary, Head Government Affairs Europe, Novartis International AG› Mr Pierre-Philippe Sagnier, Vice President, Global Market Access HEOR General Medicine & HTA Policy, Bayer Health Care Pharma› Mr Steve Wooding, Vice President, Head of Market Access, Janssen EMEA› Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ› Dr Antonio Sarria-Santamera, Director, AETS› Mr Adam Plich, Head of Market Access Europe, TEVA
Keynote panel discussion: Pharmaceutical pricing & access in the age of austerity
10.30 Speed networking followed by morning refreshments
COUNTRY SPECIFIC POLICY UPDATES & INDUSTRY EXPERIENCES
11.15 UK: The impact of devolution on value based pricing and the PPRS
› Professor Angela Timoney, Chairman, Scottish Medicines Consortium
UK: The impact of devolution on value based pricing and the PPRS
11.45 UK: Panel discussion: practical experiences with reimbursement and pricing in UK
› Dr Shane Gordon, GP & Chief Officer Designate, North East Essex Clinical Commissioning Group; Clinical Commissioning Co-Lead, NHS Alliance› Mr Steve Wooding, Vice President, Head of Market Access, Janssen EMEA› Mr Patrick Hopkinson, Director Market Access & External Affairs, Bristol-Myers Squibb Pharmaceuticals Ltd UK› Jim Furniss, VP, Market Access, GfK Bridgehead
UK: Panel discussion: practical experiences with reimbursement and pricing in UK
12.15 SPAIN: The role of HTA in a diverse and centralised healthcare system
› Dr Antonio Sarria-Santamera, Director, AETS
SPAIN: The role of HTA in a diverse and centralised healthcare system
12.40 Lunch
13.40 GERMANY: Health care policies including AMNOG and mandatory rebates that are shaping market realities in Germany
› Dr Engelbert Günster, Country Manager Germany, Boehringer Ingelheim Pharma GmbH & Co. KG
GERMANY: Health care policies including AMNOG and mandatory rebates that are shaping market realities in Germany
14.05 GERMANY: Results of AMNOG early benefit assessment and price negotiations based on benefit category
› Dr Thomas Mueller, Head of Pharmaceuticals, G-BA Germany
GERMANY: Results of AMNOG early benefit assessment and price negotiations based on benefit category
14.25 Panel discussion: practical experiences with reimbursement and pricing in Germany
› Dr Frank Weber, Senior Vice President EU and Global Medical Advisor, InterMune› Ms Corinne Savill, Global Head of Pricing and Market Access, Novartis Pharma AG› Ms Martina Barwig, Head of Health Technology Assessment, Lilly Deutschland GmbH
Panel discussion: practical experiences with reimbursement and pricing in Germany
14.55 France: Update on the new HTA assessment model and practical experiences from industry
› Professor Lise Rochaix, Member of the Board, HAS› Dr Frank Weber, Senior Vice President EU and Global Medical Advisor, InterMune› Mr Pierrick Rollet, Vice President Global Head Market Access GSK Rare Diseases, GlaxoSmithKline
France: Update on the new HTA assessment model and practical experiences from industry
15.40 Afternoon refreshments
16.10 Turn Apples into oranges and lemons into lemonade
· Use virtual population simulation to communicate the value of a medicine in a way that is understood by all parties·Leverage healthcare informatics, analytics and modeling to show economic value in specific populations
› Mika Newton, VP, Sales and Marketing, Archimedes Inc
Turn Apples into oranges and lemons into lemonade
16.40 POLAND: Clarifying the rules of the Polish reimbursement system, the transparency of reimbursement decision making processes, and the main problems and challenges for HTA in Poland
› Ms Anna Brzezinska, Director of Health Technology Assessment Department, Agency of Health Technology Assessment
POLAND: Clarifying the rules of the Polish reimbursement system, the transparency of reimbursement decision making processes, and the main problems and challenges for HTA in Poland
17.00 SCANDINAVIA: The new market access market in Scandinavia: innovative medicines within oncology
•How are the 3 Scandinavian markets responding to the new generation of targeted but more expensive medicines?•How do the various Scandinavian health care systems try to manage the difficult question of optimization?•What partnership solutions may be available?
› Mr Peter Hertzman, Head of Market Access & External Affairs, Bristol-Myers Squibb Nordic Region
SCANDINAVIA: The new market access market in Scandinavia: innovative medicines within oncology
17.30 Close of day one and networking drinks reception
........(계속)
☞ 자세한 내용은 내용바로가기를 이용하시기 바랍니다.